Indivior PLC (INDV.L)
- Reuters
Indivior reaches $86 million opioid settlement with 16 US states
NEW YORK (Reuters) -Indivior reached an $86 million settlement with 16 U.S. states over the drug manufacturer's alleged role in spreading opioid addiction across the United States, New York Attorney General Letitia James said on Friday. James said the settlement in principle concerned Indivior's manufacture of buprenorphine-based products meant to treat opioid abuse, but which allegedly can fuel addiction if misused.
- Zacks
Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates
Indivior (INDV) delivered earnings and revenue surprises of 10% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
Indivior shares soar on $100 million buyback, opioid addiction drug sales rise
(Reuters) -Specialty pharmaceutical company Indivior launched a $100 million share buyback on Thursday after logging a higher profit in the second quarter, helped by strong demand for its opioid addiction treatment, boosting its shares as much as 22%. The London-listed company, which recently shifted its primary listing to the United States, said revenue for the opioid addiction treatment Sublocade rose 24% in the second quarter to $192 million. Indivior faces intense competition from the launch of a rival drug Brixadi by Swedish drugmaker Camurus, while the end of pandemic-relief measures has led to loss of coverage in the United States for some people enrolled in government-backed Medicaid plans.
